ABSTRACT Docetaxel, a second-generation taxane, has been a cornerstone in the treatment of various cancers due to its potent antitumor activity. However, its clinical application is limited by issues such as poor solubility, systemic toxicity, and drug resistance. Nanoformulated docetaxel offers a promising solution by enhancing drug delivery, improving bioavailability, and minimizing side effects. This review delves into the various types of nanoformulations developed for docetaxel, their mechanisms of action, recent clinical advancements, and future directions. By synthesizing recent research and clinical trials, this review aims to provide a comprehensive understanding of the current state and potential of nanoformulated  docetaxel in cancer therapy.